Medicines Co.’s Angiox Heart Drug Wins U.K. Cost Agency Approval

Medicines Co.’s Angiox can be given to adults who suffer a form of heart attack known as an ST- segment elevation myocardial infarction, or STEMI, the U.K.’s medical-cost regulator said.

Angiox can be given with aspirin and clopidogrel to STEMI patients who are undergoing primary percutaneous coronary intervention, the National Institute for Health and Clinical Excellence said in guidelines published today. The agency, also known as NICE, rules on which treatments the U.K.’s National Health Service will fund.

To contact the reporter on this story: Andrea Gerlin in London at agerlin@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.